celecoxib has been researched along with Adenomatous Polyps in 10 studies
Adenomatous Polyps: Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 9.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| " Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95)." | 5.27 | Celecoxib use and circulating oxylipins in a colon polyp prevention trial. ( Alberts, DS; Hammock, BD; Lance, P; Martinez, JA; Roe, DJ; Schriewer, A; Thompson, PA; Wertheim, BC; Yang, J, 2018) |
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 5.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure." | 2.71 | Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. ( Anderson, WF; Bertagnolli, M; Finn, P; Fowler, R; Hawk, E; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez, JA | 1 |
| Yang, J | 1 |
| Wertheim, BC | 1 |
| Roe, DJ | 1 |
| Schriewer, A | 1 |
| Lance, P | 1 |
| Alberts, DS | 1 |
| Hammock, BD | 1 |
| Thompson, PA | 1 |
| Kraus, S | 1 |
| Hummler, S | 1 |
| Toriola, AT | 1 |
| Poole, EM | 1 |
| Scherer, D | 1 |
| Kotzmann, J | 1 |
| Makar, KW | 1 |
| Kazanov, D | 1 |
| Galazan, L | 1 |
| Naumov, I | 1 |
| Coghill, AE | 1 |
| Duggan, D | 1 |
| Gigic, B | 1 |
| Arber, N | 2 |
| Ulrich, CM | 1 |
| Lynch, PM | 1 |
| Burke, CA | 1 |
| Phillips, R | 1 |
| Morris, JS | 1 |
| Slack, R | 1 |
| Wang, X | 1 |
| Liu, J | 1 |
| Patterson, S | 1 |
| Sinicrope, FA | 1 |
| Rodriguez-Bigas, MA | 1 |
| Half, E | 1 |
| Bulow, S | 1 |
| Latchford, A | 1 |
| Clark, S | 1 |
| Ross, WA | 1 |
| Malone, B | 1 |
| Hasson, H | 1 |
| Richmond, E | 1 |
| Hawk, E | 3 |
| Thakkar, K | 1 |
| Fishman, DS | 1 |
| Gilger, MA | 1 |
| Solomon, SD | 2 |
| McMurray, JJ | 1 |
| Pfeffer, MA | 1 |
| Wittes, J | 2 |
| Fowler, R | 2 |
| Finn, P | 1 |
| Anderson, WF | 1 |
| Zauber, A | 1 |
| Bertagnolli, M | 1 |
| Eagle, CJ | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Tang, J | 1 |
| Rosenstein, RB | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Zauber, AG | 1 |
| Levin, B | 1 |
| Psaty, BM | 1 |
| Potter, JD | 1 |
| Lee, YH | 1 |
| Ji, JD | 1 |
| Song, GG | 1 |
| Viner, JL | 1 |
| Chau, I | 1 |
| Cunningham, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients[NCT00033371] | Phase 2 | 205 participants (Actual) | Interventional | 2001-12-13 | Completed | ||
| Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722772] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722811] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage Change in Global Colorectal Polyps burden (NCT00033371)
Timeframe: 6 months
| Intervention | percentage change of total Polyps burden (Mean) |
|---|---|
| Arm I: Celecoxib and Placebo | -27 |
| Arm II: Celecoxib and Eflornithine | -40 |
To determine the relative tolerability and safety of celecoxib + DFMO in FAP study participants. Includes only adverse events that occurred in at least 5% of the patients or a patient exhibited at least 1 grade 3 toxicity. (NCT00033371)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| High-frequency hearing loss | Fatigue | Diarrhoea | Heartburn/dyspepsia | Mucositis/stomatitis | Nausea/vomiting | Gout | Headache | |
| Arm I:Celecoxib, 400 mg p.o. BID Plus DFMO Placebo ( 60 Partic | 4 | 11 | 6 | 4 | 11 | 6 | 0 | 5 |
| Arm II: Celecoxib, 400 mg p.o. BID Plus DFMO 0.5 gm/m2/Day Rou | 7 | 3 | 4 | 2 | 15 | 7 | 1 | 1 |
Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline & 6 months by region and landmark and summed over all matched regions on number of polyps >2 mm to calculate total number of polyps >2 mm at baseline & 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline & 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days. (NCT00033371)
Timeframe: Baseline up to 6 months
| Intervention | percentage change in polyp count (Mean) | ||
|---|---|---|---|
| ITT All | ITT Measurable | ITT Evaluable | |
| Arm I: Celecoxib and Placebo | -1 | -1 | 10 |
| Arm II: Celecoxib and Eflornithine | -11 | -13 | -8 |
1 review available for celecoxib and Adenomatous Polyps
| Article | Year |
|---|---|
Colorectal polyps in childhood.
Topics: Adenomatous Polyps; Adolescent; Age of Onset; Celecoxib; Child; Child, Preschool; Colonic Polyps; Co | 2012 |
6 trials available for celecoxib and Adenomatous Polyps
| Article | Year |
|---|---|
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Topics: Adenomatous Polyps; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood | 2018 |
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col | 2013 |
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
Topics: Adenomatous Polyps; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cy | 2016 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactone | 2007 |
3 other studies available for celecoxib and Adenomatous Polyps
| Article | Year |
|---|---|
Risks and benefits of celecoxib to prevent recurrent adenomas.
Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celec | 2006 |
The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Topics: Adenomatous Polyps; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relati | 2007 |
Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; | 2002 |